36 Versus 42 Hour Time Interval From Ovulation to Intrauterine Insemination

Infertility Clinical Trial

Official title:

36 Versus 42 Hour Time Interval From Ovulation Induction to Intrauterine Insemination in Stimulated Cycles With GnRH Antagonists

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02210611
• Other study ID #: 0038-14-EMC
• Status: Terminated
• Phase: N/A
• Start date: January 2015
• Est. completion date: April 29, 2018

Study information

• Verified date: August 2019
• Source: HaEmek Medical Center, Israel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to prove that a higher clinical pregnancy rate can be achieved with a 42 to 44 hour time interval between ovulation trigger and intrauterine insemination than a 36 to 38 hour time interval in stimulated cycles utilizing gonadotropins and GnRH antagonists.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 71
• Est. completion date: April 29, 2018
• Est. primary completion date: April 29, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 17 Years to 44 Years

Eligibility

Inclusion Criteria:

1. Patients who can be monitored for follicle growth and hormone measurements on the day of ovulation trigger, or one day before.

2. Patients who have no more than 4 follicles of 14 mm or more

3. Patients who have no more than 6 follicles of 10 mm or more

Exclusion Criteria:

1. Patients who cannot give informed consent to language or comprehension barriers

2. Patients who are deemed to be at high risk for high order multiple gestations

3. Patients who cannot be monitored on the day of hCG administration or one day before

Related Conditions & MeSH terms

• Infertility

Intervention

Procedure:
• Intrauterine Insemination 36 hours
Intrauterine insemination 36 hours after ovulation induction
• Intrauterine Insemination 42 hours
Intrauterine insemination 42 hours after ovulation induction

Locations

Country	Name	City	State
Israel	Emek Medical Center	Afula

Sponsors (1)

Lead Sponsor	Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical pregnancy rate		4 weeks following insemination